InMode Stock Forecast, Price & News

+0.93 (+1.01 %)
(As of 06/17/2021 01:14 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume15,932 shs
Average Volume745,345 shs
Market Capitalization$2.96 billion
P/E Ratio40.99
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive INMD News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

InMode logo

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.29 out of 5 stars

Medical Sector

885th out of 2,102 stocks

Electromedical Equipment Industry

22nd out of 62 stocks

Analyst Opinion: 1.5Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

InMode (NASDAQ:INMD) Frequently Asked Questions

Is InMode a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" InMode stock.
View analyst ratings for InMode
or view top-rated stocks.

What stocks does MarketBeat like better than InMode?

Wall Street analysts have given InMode a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InMode wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting InMode?

InMode saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 1,990,000 shares, an increase of 17.8% from the May 13th total of 1,690,000 shares. Based on an average daily trading volume, of 669,800 shares, the short-interest ratio is currently 3.0 days. Approximately 8.2% of the company's stock are sold short.
View InMode's Short Interest

When is InMode's next earnings date?

InMode is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for InMode

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) posted its quarterly earnings results on Wednesday, May, 5th. The healthcare company reported $0.69 EPS for the quarter, topping the Zacks' consensus estimate of $0.41 by $0.28. The healthcare company earned $65.52 million during the quarter, compared to analysts' expectations of $51.14 million. InMode had a net margin of 41.20% and a trailing twelve-month return on equity of 38.62%. The company's quarterly revenue was up 62.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.30 earnings per share.
View InMode's earnings history

How has InMode's stock been impacted by Coronavirus?

InMode's stock was trading at $24.40 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INMD shares have increased by 277.3% and is now trading at $92.05.
View which stocks have been most impacted by COVID-19

What guidance has InMode issued on next quarter's earnings?

InMode issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided EPS guidance of 2.600-2.750 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.500. The company issued revenue guidance of $270 million-$280 million, compared to the consensus revenue estimate of $264.47 million.

What price target have analysts set for INMD?

5 Wall Street analysts have issued 1-year target prices for InMode's stock. Their forecasts range from $84.00 to $104.00. On average, they expect InMode's share price to reach $93.80 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts' price targets for InMode
or view top-rated stocks among Wall Street analysts.

Who are InMode's key executives?

InMode's management team includes the following people:
  • Mr. Moshe Mizrahy, Chairman & CEO (Age 68, Pay $216k)
  • Mr. Yair Malca, Chief Financial Officer (Age 43, Pay $429k)
  • Dr. Michael Kreindel, CTO & Director (Age 53, Pay $217k)
  • Mr. Shakil Lakhani, Pres of North America (Age 38, Pay $2.05M)
  • Dr. Spero Theodorou M.D., Chief Medical Officer (Age 49, Pay $1.62M)

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode CEO Moshe Mizrahy on Moshe Mizrahy has an approval rating of 100% among InMode's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of InMode's key competitors?

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an initial public offering on Thursday, August 8th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a number of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (4.95%), William Blair Investment Management LLC (2.20%), Renaissance Technologies LLC (1.52%), Standard Life Aberdeen plc (1.44%), Morgan Stanley (1.43%) and Thrivent Financial for Lutherans (1.39%).

Which institutional investors are selling InMode stock?

INMD stock was sold by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd., Miura Global Management LLC, Noked Israel Ltd, Prospect Capital Advisors LLC, Point72 Asset Management L.P., Wasatch Advisors Inc., Loomis Sayles & Co. L P, and Victory Capital Management Inc..

Which institutional investors are buying InMode stock?

INMD stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, William Blair Investment Management LLC, Thrivent Financial for Lutherans, Migdal Insurance & Financial Holdings Ltd., Standard Life Aberdeen plc, Fred Alger Management LLC, Morgan Stanley, and Man Group plc.

How do I buy shares of InMode?

Shares of INMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $92.05.

How much money does InMode make?

InMode has a market capitalization of $2.94 billion and generates $206.11 million in revenue each year. The healthcare company earns $75.03 million in net income (profit) each year or $1.78 on an earnings per share basis.

How many employees does InMode have?

InMode employs 311 workers across the globe.

What is InMode's official website?

The official website for InMode is

Where are InMode's headquarters?

InMode is headquartered at TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200.

How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The healthcare company can be reached via phone at 972-4909-6313 or via email at [email protected]

This page was last updated on 6/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.